Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

VLTR-559 was well tolerated at target clinical dose with a safety profile similar to approved short-acting anti-VEGF therapies for wet AMD Data featured in an oral presentation at the at the ...

Ivonescimab’s progression-free survival data bode well for an upcoming overall survival readout, according to Truist analysts ...

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated ...

Simultaneous PD-1/VEGF/CTLA-4 blockade aims to compress multi-drug regimens into a single infusion, raising questions about ...

Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus ...

On cycle 1 day 8, CS2009 induced notable, dose-dependent upregulation of Ki67 (proliferation due to PD-1 and CTLA-4 blockade) and ICOS (activation due to CTLA-4 blockade) expression on both CD4+ and ...

Ivonescimab combined with chemotherapy significantly improved progression-free survival (PFS) compared with Tevimbra ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi ...